Number of pregnancies exposed to isotretinoin between 2004 and 2019 in GePaRD by age group and year of beginning of pregnancy.

Number of pregnancies exposed to isotretinoin between 2004 and 2019 in GePaRD by age group and year of beginning of pregnancy.</p

Prescriptions of Isotretinoin dispensed to girls and women aged 13–49 years between 2004 and 2019 in GePaRD: Distribution of the specialty of the prescribing physician.

Prescriptions of Isotretinoin dispensed to girls and women aged 13–49 years between 2004 and 2019 in GePaRD: Distribution of the specialty of the prescribing physician.</p

Number of pregnancies exposed to isotretinoin between 2004 and 2019 in GePaRD, mother’s age at pregnancy beginning and type of pregnancy outcome: base case and sensitivity analyses considering delayed elimination (exposure window assigned to the last dispensation before pregnancy was extended by 1 month), a fixed supply of 30 days, and the possibility that lower or higher doses than the DDD for isotretinoin (30 mg) were used.

Number of pregnancies exposed to isotretinoin between 2004 and 2019 in GePaRD, mother’s age at pregnancy beginning and type of pregnancy outcome: base case and sensitivity analyses considering delayed elimination (exposure window assigned to the last dispensation before pregnancy was extended by 1 month), a fixed supply of 30 days, and the possibility that lower or higher doses than the DDD for isotretinoin (30 mg) were used.</p

Age-specific and age-standardized prevalence with 95% CIs (shaded area) of isotretinoin use per 1,000 girls and women aged 13–49 years between 2004 and 2019 in the GePaRD.

CI, confidence interval; GePaRD, German Pharmacoepidemiological Research Database.</p

STROBE Statement—checklist of items that should be included in reports of observational studies.

STROBE Statement—checklist of items that should be included in reports of observational studies.</p

Number of girls and women aged 13–49 years with at least 1 dispensation of isotretinoin between 2004 and 2019 in GePaRD by age group and year of prescription.

Number of girls and women aged 13–49 years with at least 1 dispensation of isotretinoin between 2004 and 2019 in GePaRD by age group and year of prescription.</p

Malformations observed in live-born children exposed to isotretinoin during pregnancy in GePaRD between 2004 and 2019.

Malformations observed in live-born children exposed to isotretinoin during pregnancy in GePaRD between 2004 and 2019.</p

Supplemental material for The association between migraine and hospital readmission due to pain after surgery: A hospital registry study

<p>Supplemental material for The association between migraine and hospital readmission due to pain after surgery: A hospital registry study by Katharina Platzbecker, Megan Behua Zhang, Tobias Kurth, Maira Isabella Rudolph, Katharina Eikermann-Haerter, Rami Burstein, Matthias Eikermann and Timothy Houle in Cephalalgia</p